Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Apr 15, 2007 (Vol. 27, No. 8)

BioScreening - Organic Compounds for Screening

  • Interesting links
  • Couldn't this at least be designed better?
Let’s see. The opening page of this one has ads for chemistry software, Sigma-Aldrich, and Amazon.com. Does that raise any red flags for you? It did for me, as the displays were: 1) obnoxiously wiggling/moving and 2) about as unpleasantly mish-mashed together as they could be. Do advertisers ever look to see how their ads are displayed? Sigh. OK, this site is about more than just ads or I wouldn’t be talking about it here. To the point, BioScreening provides numerous useful links to information. They include CombiChem libraries, an A to Z list of companies involved in bioscreening, compound libraries, software, pharmacological standards libraries, specialty chemicals, and natural products, among others. The links, unfortunately, are in tiny print on the ad-dominated opening page, so you’ll have to squint to find what you’re after. I suppose it is worth it, but just barely.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »